Noncytolytic extraction of soluble antigens from leukemic blast cells (L2C-EN)

Summary Lithium 3,5 diiodosalicylate (LIS), a chemical utilized for the noncytolytic extraction of cell surface antigens, was used in this study to extract glycoproteins from the cell membranes of L₂C-EN leukemic blast cells. The crude soluble antigen (LIS-L₂C) preparation was found to confer immunoprotection in syngeneic guinea pigs against a lethal challenge of L₂C-EN. Titration of the crude LIS-L₂C soluble antigen extract revealed that 1 mg antigen gave 100% protection against a 2×10⁵ viable tumor cell challenge 2 weeks after immunization and that immunizing doses of 0.1 mg, 0.25 mg, and 0.5 mg soluble antigen afforded 17%, 66%, and 83% protection, respectively. The specificity of this immune response was demonstrated by the failure of guinea pigs immunized with 1 mg LIS extract prepared from another guinea pig tumor (line 10 hepatoma) to be refractory to a similar L₂C tumor cell challenge. A cell-mediated immune response to the LIS-L₂C soluble antigen was observed in animals, based on a positive delayed hypersensitivity response to the soluble antigen 5 weeks after immunization. Similarly, in vitro testing revealed a specific blastogenic recognition of the soluble antigen by immune leukocytes.